Issue Information.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 3, p. 231, doi. 10.1002/cpdd.975
- Publication type:
- Article
Works matching IS 2160763X AND DT 2023 AND VI 12 AND IP 3
Results: 14
1
2
2022 CPDD Reviewers.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 3, p. 343, doi. 10.1002/cpdd.1242
- Publication type:
- Article
3
Evaluation of a Low‐Fat Low‐Calorie Meal on the Relative Bioavailability of Trametinib and Dabrafenib: Results From a Randomized, Open‐Label, 2‐Part Study in Healthy Participants.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 3, p. 333, doi. 10.1002/cpdd.1220
- By:
- Publication type:
- Article
4
A Randomized, Double‐Blind, Parallel Design Thorough QT Study With a Nested Crossover to Compare the Cardiac Safety of Amiselimod With Placebo and Positive Control in Healthy Volunteers.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 3, p. 236, doi. 10.1002/cpdd.1210
- By:
- Publication type:
- Article
5
A Single‐center, Open‐label, Parallel Control Study Comparing the Pharmacokinetics and Safety of a Single Oral Dose of Roflumilast and Its Active Metabolite Roflumilast N‐oxide in Healthy Chinese and Caucasian Volunteers.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 3, p. 314, doi. 10.1002/cpdd.1209
- By:
- Publication type:
- Article
6
Pharmacokinetics and Comparative Bioavailability of Test or Reference Capecitabine and Discrepant Pharmacokinetics Among Various Tumors in Chinese Solid Cancer Patients.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 3, p. 324, doi. 10.1002/cpdd.1202
- By:
- Publication type:
- Article
7
Pharmacokinetic and Bioequivalent Study of Potassium Chloride Sustained‐Release Tablet Under Different Dietary Conditions in Healthy Chinese Subjects.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 3, p. 267, doi. 10.1002/cpdd.1180
- By:
- Publication type:
- Article
8
Evaluation of Potential Food Effects and Drug Interactions With Lansoprazole in Healthy Adult Volunteers Receiving Futibatinib.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 3, p. 294, doi. 10.1002/cpdd.1196
- By:
- Publication type:
- Article
9
Effect of Futibatinib on Cardiac Repolarization: Results of a Randomized, Controlled, Double‐Blind, QT/QTc, Phase 1 Study in Healthy Subjects.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 3, p. 304, doi. 10.1002/cpdd.1195
- By:
- Publication type:
- Article
10
Effect of Pevonedistat, an Investigational NEDD8‐Activating Enzyme Inhibitor, on the QTc Interval in Patients With Advanced Solid Tumors.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 3, p. 257, doi. 10.1002/cpdd.1194
- By:
- Publication type:
- Article
11
Population Pharmacokinetic Analysis of Valsartan in Healthy Chinese Subjects.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 3, p. 249, doi. 10.1002/cpdd.1181
- By:
- Publication type:
- Article
12
Clinical Drug‐Drug Interaction Between Vatiquinone, a 15‐Lipoxygenase Inhibitor, and Rosuvastatin, a Breast Cancer Resistance Protein Substrate.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 3, p. 279, doi. 10.1002/cpdd.1199
- By:
- Publication type:
- Article
13
Effect of a High‐Fat Meal on Single‐Dose Rencofilstat (CRV431) Oral Bioavailability in Healthy Human Subjects.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 3, p. 287, doi. 10.1002/cpdd.1179
- By:
- Publication type:
- Article
14
Pharmacokinetics, Bioequivalence, and Safety of 2 Formulations of Hydroxychloroquine Tablets in Healthy Chinese Volunteers Under Fasting and Fed Conditions.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 3, p. 273, doi. 10.1002/cpdd.1166
- By:
- Publication type:
- Article